Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
IJPR-Iranian Journal of Pharmaceutical Research. 2017; 16 (1): 238-248
in English | IMEMR | ID: emr-187965

ABSTRACT

Leukemia is a blood disease that creates from inhibition of differentiation and increased proliferation rate. The nature has been known as a rich source of medically useful substances. High diversity of bioactive molecules, extracted from marine invertebrates, makes them as ideal candidates for cancer research. The study has been done to investigate cytotoxic effects of dichloromethane brittle star extract and doxorubic in on EL4 cancer cells. Blood cancer EL4 cells were cultured and treated at different concentrations of Brittle Star [Ophiocoma erinaceus] dichloromethane extract at 24, 48 and 72 h. Cell toxicity was studied using MTT assay. Cell morphology was examined using an invert microscope. Further, apoptosis was examined using Annexin V-FITC, propodium iodide, DAPI, and Acridine orange/propodium iodide staining. Eventually, the apoptosis pathways were analyzed using measurement of Caspase 3 and 9 activity. The statistical analysis was performed using SPSS, ANOVA software, and Tukey's test. P < 0.05 was considered to be significant. MTT assay and morphological observations showed that dichloromethane extract can inhibit cell growth in a dose dependent. The results considered 32 micro g/mL of the extract as IC[50]. Also, doxorubicin suppressed EL4 proliferation as IC[50]= 32 micro g/mL. All experiments related to apoptosis analysis confirmed that dichloromethane Brittle Star extract and doxorubic in have a cytotoxic effect on EL4 cells in IC[50] concentration. The study showed that dichloromethane Brittle Star extract is as an adjunct to doxorubicin in treatment of leukemia cells

SELECTION OF CITATIONS
SEARCH DETAIL